Prevention of Contrast Induced Nephropathy by Erythropoietin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 142 participants.
Also called NCT01364402
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 142 participants
- Sponsor
- Western Galilee Hospital-Nahariya
- Registry
-
NCT01364402
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Israel
- Registry status
- Unknown status
Technical summary
Registry record NCT01364402. Randomized; quadruple masking; primary purpose prevention. Start 2011-08 (registry gives no type); primary completion 2013-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prevention of Contrast Induced Nephropathy by Erythropoietin
- Condition
- Diabetes
- Condition
- Chronic Kidney Insufficiency
- Intervention (Drug)
- Epoetin beta
- Intervention (Drug)
- Saline 0.9%
- Lead sponsor
- Western Galilee Hospital-Nahariya
Record details
- Record id
cardio:ct-nct01364402- Content hash
d8e6aa12ca26a0d4d73979603551ed262d1ca8dcfea7062d94511da01fb3ac01